Benign Breast Disease: Toward Molecular Prediction of Breast Cancer Risk
Abstract
Optimal early detection and prevention strategies for breast cancer are predicated on our ability to identify individuals at significantly increased risk for this disease. Unfortunately only a minority of the over 200,000 women who are diagnosed with breast cancer in the US each year are recognized as being at significantly increased risk. The purpose of this Center is to bring molecular risk prediction for breast cancer into the clinical arena. This will require progress on three fronts of scientific investigation: (i) establishment of a tissue repository of benign breast disease (BBD); (ii) assessment of potential biomarkers of risk in this tissue set and (iii) discovery of new, potentially relevant biomarkers of risk. We have made significant progress on these aims. Our 25-year cohort includes 9,087 women with BBD, 707 of whom have developed a breast cancer to date. We have completed the cohort follow-up by questionnaire. All benign histopathology has been read. For those women who developed breast cancer, we have cancer tissue for 93% of those diagnosed at Mayo and 55% diagnosed outside Mayo. We are studying biomarkers (COX-2, centrosome status, cyclin D1, etc) in several relevant subsets including atypia. For discovery, 14 BBD samples are growing successfully thus far.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jun 01, 2005
- Accession Number
- ADA442889
Entities
People
- Lynn C. Hartmann
Organizations
- Mayo Clinic